Once again, the Johnson & Johnson Innovation team fully participated at BIO-Europe®, taking place this year in Berlin on 6-8 November. Attended by more than 4,000 biotech and pharma leaders and over 2,000 companies, BIO-Europe® is Europe’s largest life science partnering conference and a great place for the JOHNSON & JOHNSON Innovation team to “make the connection”.
With over 280 partnering meetings scheduled, it was a jam-packed couple of days for the team. Speaking event highlights included Richard Mason (Head, Johnson & Johnson Innovation, EMEA), Nerida Scott (VP, New Ventures & Transactions, Johnson & Johnson Innovation, EMEA), Rosemary Liu (Business Development Manager, Johnson & Johnson Innovation, EMEA) and Nicholas Franco (VP, JBD, Actelion), who shared their experiences and expertise alongside other industry leaders.`
As always, one of the high-profile features of the conference was Startup Slam, organised and sponsored by Johnson & Johnson Innovation for the fourth time. Hosted by Emma Kohring (Innovation Communications Leader, Johnson & Johnson Innovation, EMEA) and Marek Tyl from the Innovation Forum, the judging panel comprised Pavithra Sundaresan (Senior Director, New Ventures and Transactions, Immunology, Johnson & Johnson Innovation, EMEA) together with a number of other leading VC’s and experts.
Following the agreed pitching format, eight shortlisted European start-ups each had three minutes to pitch their innovation to a packed room of over 150 delegates and journalists, followed by a Q&A from the judges. The innovations presented ranged from microbe-based therapeutics to using Artificial Intelligence (AI) to develop diagnostic solutions for Alzheimer’s Disease.
Thomas de Vlaam, CEO of Amylon Therapeutics, was pronounced the winner of Startup Slam. Amylon Therapeutics targets Central Nervous System (CNS) disorders through an ultra-genetics approach, focusing on rare genetic disorders that can serve as a possible gateway to more frequently occurring indications. In addition to receiving a complimentary registration to next year’s BIO-Europe Spring®, Amylon Therapeutics also has the opportunity to accelerate their platform even further by entering into a year-long no fee arrangement to become a JOHNSON & JOHNSON Innovation, JLINX community member. Read the full press release here. “Best Pitch” was awarded to Joana Simões Correia of Exogenus Therapeutics.
It was a fantastic competition with lots of challenging questions from the judges. If you missed it, watch the full stream here.